Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$123.50 USD
+5.98 (5.09%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $169.00 +45.50 (36.84%) 6:40 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 1 - 20 ( 663 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: EMBARK-ing on a New Year with Sights Set on ELEVIDYS Label Expansion
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficacy Supplement to ELEVIDYS'' BLA Accepted; Review Goal Date of June 21
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 21224
Provider: Stock Traders Daily
Analyst: Research Department